These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26577454)

  • 21. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
    Rao CV; Steele VE; Swamy MV; Patlolla JM; Guruswamy S; Kopelovich L
    Cancer Res; 2009 Oct; 69(20):8175-82. PubMed ID: 19826045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
    Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
    Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
    Li KW; Wang SH; Wei X; Hou YZ; Li ZH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma.
    Yang C; Zhang Y; Zhang Y; Zhang Z; Peng J; Li Z; Han L; You Q; Chen X; Rao X; Zhu Y; Liao Z
    Int J Oncol; 2015 Sep; 47(3):909-17. PubMed ID: 26202311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation.
    Whang YM; Kim MJ; Cho MJ; Yoon H; Choi YW; Kim TH; Chang IH
    J Cell Physiol; 2019 Aug; 234(8):13083-13096. PubMed ID: 30549029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
    Seager CM; Puzio-Kuter AM; Patel T; Jain S; Cordon-Cardo C; Mc Kiernan J; Abate-Shen C
    Cancer Prev Res (Phila); 2009 Dec; 2(12):1008-14. PubMed ID: 19952358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
    Akeno N; Miller AL; Ma X; Wikenheiser-Brokamp KA
    Oncogene; 2015 Jan; 34(5):589-99. PubMed ID: 24469052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
    PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 and rapamycin are additive.
    Christy B; Demaria M; Campisi J; Huang J; Jones D; Dodds SG; Williams C; Hubbard G; Livi CB; Gao X; Weintraub S; Curiel T; Sharp ZD; Hasty P
    Oncotarget; 2015 Jun; 6(18):15802-13. PubMed ID: 26158292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.
    Schultz L; Albadine R; Hicks J; Jadallah S; DeMarzo AM; Chen YB; Nielsen ME; Gonzalgo ML; Sidransky D; Schoenberg M; Netto GJ
    Cancer; 2010 Dec; 116(23):5517-26. PubMed ID: 20939013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
    Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
    PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
    Makrakis D; Wright JL; Roudier MP; Garcia J; Vakar-Lopez F; Porter MP; Wang Y; Dash A; Lin D; Schade G; Winters B; Zhang X; Nelson P; Mostaghel E; Cheng HH; Schweizer M; Holt SK; Gore JL; Yu EY; Lam HM; Montgomery B
    Clin Genitourin Cancer; 2023 Apr; 21(2):265-272. PubMed ID: 36710146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
    PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
    Makboul R; Refaiy A; Abdelkawi IF; Hameed DA; Elderwy AA; Shalaby MM; Merseburger AS; Hussein MR
    Pathol Res Pract; 2016 May; 212(5):385-92. PubMed ID: 26916953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
    Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
    Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of microRNA‑194‑5p inhibits hypopharyngeal carcinoma cell proliferation, migration and invasion by targeting SMURF1 via the mTOR signaling pathway.
    Xu S; Hui L; Yang N; Wang Y; Zhao N; Jiang XJ
    Int J Oncol; 2019 Apr; 54(4):1245-1255. PubMed ID: 30720112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.